|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C8orf34 |
Gene summary for C8ORF34 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C8orf34 | Gene ID | 116328 |
| Gene name | chromosome 8 open reading frame 34 | |
| Gene Alias | VEST-1 | |
| Cytomap | 8q13.2 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q49A92 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 116328 | C8orf34 | AEH-subject1 | Human | Endometrium | AEH | 1.90e-12 | 4.04e-01 | -0.3059 |
| 116328 | C8orf34 | AEH-subject4 | Human | Endometrium | AEH | 4.66e-15 | 5.21e-01 | -0.2657 |
| 116328 | C8orf34 | AEH-subject5 | Human | Endometrium | AEH | 6.41e-07 | 2.48e-01 | -0.2953 |
| 116328 | C8orf34 | EEC-subject2 | Human | Endometrium | EEC | 7.71e-23 | 5.57e-01 | -0.2607 |
| 116328 | C8orf34 | EEC-subject5 | Human | Endometrium | EEC | 2.59e-02 | 1.67e-01 | -0.249 |
| 116328 | C8orf34 | RNA-P10T2-P10T2-1 | Human | Lung | AAH | 8.97e-08 | 1.26e+00 | -0.1271 |
| 116328 | C8orf34 | RNA-P10T2-P10T2-2 | Human | Lung | AAH | 2.92e-09 | 1.31e+00 | -0.1406 |
| 116328 | C8orf34 | RNA-P10T2-P10T2-3 | Human | Lung | AAH | 1.54e-08 | 1.25e+00 | -0.1408 |
| 116328 | C8orf34 | RNA-P10T2-P10T2-4 | Human | Lung | AAH | 1.13e-06 | 1.21e+00 | -0.138 |
| 116328 | C8orf34 | RNA-P24T2-P24T2-2 | Human | Lung | IAC | 3.23e-03 | 1.17e+00 | 0.0057 |
| 116328 | C8orf34 | RNA-P25T1-P25T1-1 | Human | Lung | AIS | 2.43e-27 | 1.16e+00 | -0.2116 |
| 116328 | C8orf34 | RNA-P25T1-P25T1-2 | Human | Lung | AIS | 1.37e-13 | 1.14e+00 | -0.1941 |
| 116328 | C8orf34 | RNA-P25T1-P25T1-3 | Human | Lung | AIS | 4.65e-14 | 1.11e+00 | -0.2107 |
| 116328 | C8orf34 | RNA-P25T1-P25T1-4 | Human | Lung | AIS | 7.10e-27 | 1.16e+00 | -0.2119 |
| 116328 | C8orf34 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.33e-06 | 3.45e-01 | -0.0166 |
| 116328 | C8orf34 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 3.68e-10 | 4.18e-01 | -0.0132 |
| 116328 | C8orf34 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 7.51e-11 | 4.54e-01 | -0.013 |
| 116328 | C8orf34 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 1.85e-06 | 3.63e-01 | -0.0121 |
| 116328 | C8orf34 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 1.49e-04 | 6.20e-01 | -0.0961 |
| 116328 | C8orf34 | RNA-P7T1-P7T1-2 | Human | Lung | AIS | 1.02e-03 | 5.96e-01 | -0.0876 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C8orf34 | SNV | Missense_Mutation | rs775451105 | c.1022N>G | p.Asp341Gly | p.D341G | Q49A92 | protein_coding | deleterious(0.01) | probably_damaging(0.995) | TCGA-A2-A0YJ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
| C8orf34 | SNV | Missense_Mutation | c.848N>T | p.Pro283Leu | p.P283L | Q49A92 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD | |
| C8orf34 | insertion | Frame_Shift_Ins | novel | c.1445_1446insTTATGTTTTAAACACATATGGTGTCCTAGGATTTATAATTT | p.Met483TyrfsTer21 | p.M483Yfs*21 | Q49A92 | protein_coding | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| C8orf34 | deletion | Frame_Shift_Del | novel | c.969delN | p.Lys324AsnfsTer30 | p.K324Nfs*30 | Q49A92 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| C8orf34 | SNV | Missense_Mutation | c.1486N>T | p.His496Tyr | p.H496Y | Q49A92 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.979) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C8orf34 | SNV | Missense_Mutation | rs771361055 | c.1372N>A | p.Glu458Lys | p.E458K | Q49A92 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C8orf34 | SNV | Missense_Mutation | novel | c.20N>T | p.Ser7Leu | p.S7L | Q49A92 | protein_coding | tolerated_low_confidence(0.14) | unknown(0) | TCGA-VS-A9UH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| C8orf34 | SNV | Missense_Mutation | novel | c.325N>C | p.Glu109Gln | p.E109Q | Q49A92 | protein_coding | tolerated(0.22) | probably_damaging(0.991) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| C8orf34 | SNV | Missense_Mutation | c.727N>A | p.Leu243Ile | p.L243I | Q49A92 | protein_coding | deleterious(0.03) | probably_damaging(0.99) | TCGA-A6-3809-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C8orf34 | SNV | Missense_Mutation | c.957N>T | p.Lys319Asn | p.K319N | Q49A92 | protein_coding | deleterious(0) | benign(0.131) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 116328 | C8ORF34 | CLINICALLY ACTIONABLE, KINASE | irinotecan | IRINOTECAN | 22664479 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |